TALAZOPARIB, TALAZOPARIB, TALAZOPARIB, Xtandi - 40 mg soft capsules, TALAZOPARIB
C3441021
Phase 3 small_molecule active
Quick answer
TALAZOPARIB, TALAZOPARIB, TALAZOPARIB, Xtandi - 40 mg soft capsules, TALAZOPARIB for Metastatic Castration-resistant Prostate Cancer is a Phase 3 program (small_molecule) at Pfizer Ireland Pharmaceuticals Unlimited Company with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pfizer Ireland Pharmaceuticals Unlimited Company
- Indication
- Metastatic Castration-resistant Prostate Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active